Article
MHC II deficient infant identified by newborn screening program for SCID.
Immunologic research - 1 Aug 2018
Marcus Nufar, Stauber Tali, Lev Atar, Simon Amos J, Stein Jerry, Broides Arnon, Somekh Ido, Almashanu Shlomo, Somech Raz
Abstract excerpt
Newborn screening (NBS) programs for severe combined immunodeficiency (SCID), using the TREC-based assay, have enabled early diagnosis, prompt treatment, and eventually changed the natural history of affected infants. Nevertheless, it was believed that some affected infants with residual T cell, such as patients with MHC II deficiency, will be misdiagnosed by this assay. A full immune workup and genetic analysis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
